Tanzania investigating circulation of fake HIV drugs, stops local ARV production

NewsGuard 100/100 Score

BBC News reports on an investigation into the circulation of fake HIV drugs in Tanzania, writing, "Analysts say there is concern about the quality of locally made drugs given widespread corruption in political circles in the East Africa nation." Health Minister Hussein Mwinyi "has suspended three top officials and stopped local production of the antiretrovirals (ARVs) while the probe takes place," the news service notes, adding, "Mwinyi said the health ministry was alerted in August to problems with a batch of ARV drugs at the Tarime District Hospital."

"The batch, produced by the Tanzania Pharmaceutical Industry (TPI), was immediately recalled and subjected to further testing, which revealed that it was sub-standard," according to BBC. "The officials who were suspended on Wednesday work at the Medical Stores Department (MSD) and the production of all drugs by TPI has been halted while investigations are under way, the government-owned paper Tanzania Daily News reports," BBC notes. The news service adds, "The minister said out of 12,000 bottles in the fake ARV batch, 9,570 had so far been successfully recalled" (10/11).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug candidates show promise to reverse HIV immune evasion